ECSP10010476A - Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6 - Google Patents

Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6

Info

Publication number
ECSP10010476A
ECSP10010476A EC2010010476A ECSP10010476A ECSP10010476A EC SP10010476 A ECSP10010476 A EC SP10010476A EC 2010010476 A EC2010010476 A EC 2010010476A EC SP10010476 A ECSP10010476 A EC SP10010476A EC SP10010476 A ECSP10010476 A EC SP10010476A
Authority
EC
Ecuador
Prior art keywords
disorders
compounds
disorder
disease
attention deficit
Prior art date
Application number
EC2010010476A
Other languages
English (en)
Inventor
Loevezijn Arnold Van
Bakker Wouter I Iwema
Axel Stoit
Agatha A M Rensink
Jennifer Venhorst
Der Neut Martina A W Van
Haan Martin De
Cornelis G Kruse
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Publication of ECSP10010476A publication Critical patent/ECSP10010476A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

Esta invención se refiere a derivados de arilsulfonil pirazolin carboxamidina como antagonistas de receptores 5-HT6, a métodos para la preparación de estos compuestos y a novedosos intermediarios útiles para su síntesis. La invención también se refiere a los usos de tales compuestos y composiciones particularmente su uso en la administración de los mismos a pacientes para lograr un efecto terapéutico en la enfermedad de Parkinson, corea de Huntington, esquizofrenia, ansiedad, depresión, depresión maníaca, psicosis, epilepsia, trastornos obsesivos compulsivos, trastornos del ánimo, migraña, enfermedad de Alzheimer, declinación cognitiva relacionada con la edad, deterioro cognitivo leve, trastornos del sueño, trastornos de la alimentación, anorexia, bulimia, trastornos de atracones en la alimentación , ataques de pánico, acatisia, trastorno de hiperactividad y déficit de atención, trastorno de déficit de atención, abstinencia del abuso de cocaína, etanol, nicotina o benzodiazepinas, dolor, trastornos asociados con trauma espinal o daño en la cabeza, hidrocefalia, trastorno funcional del intestino, Síndrome de Intestino Irritable, obesidad y diabetes tipo 2. Los compuestos tienen la fórmula general (1): en donde los símbolos tienen los significados dados en la descripción.
EC2010010476A 2008-03-18 2010-09-13 Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6 ECSP10010476A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3746308P 2008-03-18 2008-03-18
EP08152873 2008-03-18

Publications (1)

Publication Number Publication Date
ECSP10010476A true ECSP10010476A (es) 2010-10-30

Family

ID=39639064

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010476A ECSP10010476A (es) 2008-03-18 2010-09-13 Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6

Country Status (29)

Country Link
US (3) US8563723B2 (es)
EP (2) EP2265589B1 (es)
JP (1) JP5504252B2 (es)
KR (1) KR101623357B1 (es)
CN (2) CN104003937A (es)
AR (1) AR070898A1 (es)
AU (1) AU2009226956C1 (es)
BR (1) BRPI0908738A8 (es)
CA (1) CA2717922A1 (es)
CO (1) CO6290679A2 (es)
CR (1) CR11742A (es)
DK (2) DK2265589T3 (es)
DO (2) DOP2010000276A (es)
EA (1) EA023176B1 (es)
EC (1) ECSP10010476A (es)
ES (2) ES2565184T3 (es)
HK (2) HK1201823A1 (es)
IL (1) IL207846A0 (es)
MX (1) MX2010010299A (es)
MY (1) MY155318A (es)
NZ (1) NZ587743A (es)
PH (1) PH12013502376A1 (es)
PL (2) PL2265589T3 (es)
PT (1) PT2610247T (es)
SG (1) SG183688A1 (es)
TW (1) TWI557110B (es)
UA (1) UA105629C2 (es)
WO (1) WO2009115515A1 (es)
ZA (1) ZA201006272B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079935A1 (es) * 2010-01-29 2012-02-29 Abbott Healthcare Products Bv Sintesis de derivados de pirazolin carboxamidina sustituida
HUE050962T2 (hu) * 2011-08-15 2021-01-28 Univ Utah Res Found Hiszton demetiláz inhibitor szubsztituált (E)-N'-(1-feniletilidén)-benzohidrazid származékok
SI2920165T1 (sl) * 2012-11-16 2017-02-28 Bristol-Myers Squibb Company Modulatorji dihidropirazola GPR40
CA2891551A1 (en) * 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Dihydropyrazole gpr40 modulators
BR112015010791A2 (pt) 2012-11-16 2017-07-11 Bristol Myers Squibb Co moduladores de gpr40 de di-hidropirazol
CA2948349C (en) * 2014-05-09 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pyrazole derivatives and their use as cannabinoid receptor mediators
EP3180312B1 (en) 2014-08-12 2019-10-16 Loyola University Of Chicago Indoline sulfonamide inhibitors of dape and ndm-1 and use of the same
EP3109237A1 (en) * 2015-06-22 2016-12-28 AnaMar AB Novel 5-ht2 antagonists
CN107460160A (zh) * 2017-08-23 2017-12-12 世贸天阶制药（江苏）有限责任公司 一种cho细胞无血清培养基
US10879709B2 (en) 2018-05-31 2020-12-29 National Taipei University Of Technology Power management system and operating method thereof
WO2021069567A1 (en) 2019-10-09 2021-04-15 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
EP4178982A1 (en) 2020-07-13 2023-05-17 Precirix N.V. Antibody fragment against folr1
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL367814A1 (en) * 2001-09-21 2005-03-07 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
GB0422263D0 (en) 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
SA07280510B1 (ar) 2006-09-22 2012-02-07 سولفاي فارماسوتيكالز بي . في سلفونيل بيرازول ومشتقات سلفونيل كربوكساميدين كمضادات ht6-5

Also Published As

Publication number Publication date
JP5504252B2 (ja) 2014-05-28
CN104003937A (zh) 2014-08-27
AR070898A1 (es) 2010-05-12
DK2265589T3 (en) 2016-03-21
BRPI0908738A8 (pt) 2017-10-10
EP2265589B1 (en) 2016-01-27
JP2011517443A (ja) 2011-06-09
CR11742A (es) 2011-03-03
MY155318A (en) 2015-09-30
AU2009226956A8 (en) 2010-09-23
PH12013502376B1 (en) 2015-01-12
MX2010010299A (es) 2010-12-15
PH12013502376A1 (en) 2015-01-12
ES2565184T3 (es) 2016-04-01
EA023176B1 (ru) 2016-05-31
PT2610247T (pt) 2016-07-07
DOP2010000276A (es) 2010-11-15
CO6290679A2 (es) 2011-06-20
ZA201006272B (en) 2011-05-25
AU2009226956A1 (en) 2009-09-24
DK2610247T3 (en) 2016-06-13
TWI557110B (zh) 2016-11-11
NZ587743A (en) 2012-06-29
US8563723B2 (en) 2013-10-22
HK1152708A1 (en) 2012-03-09
AU2009226956C1 (en) 2014-03-06
PL2610247T3 (pl) 2017-02-28
DOP2010000277A (es) 2011-01-31
CA2717922A1 (en) 2009-09-24
EP2265589A1 (en) 2010-12-29
EA201071083A1 (ru) 2011-04-29
CN102036967B (zh) 2014-10-15
AU2009226956B2 (en) 2013-05-23
BRPI0908738A2 (pt) 2017-06-13
US9126942B2 (en) 2015-09-08
KR101623357B1 (ko) 2016-05-23
US8901108B2 (en) 2014-12-02
EP2610247A1 (en) 2013-07-03
EP2610247B1 (en) 2016-05-25
US20140011775A1 (en) 2014-01-09
IL207846A0 (en) 2010-12-30
TW200942519A (en) 2009-10-16
UA105629C2 (uk) 2014-06-10
US20150051239A1 (en) 2015-02-19
HK1201823A1 (en) 2015-09-11
SG183688A1 (en) 2012-09-27
US20110046171A1 (en) 2011-02-24
KR20100136504A (ko) 2010-12-28
CN102036967A (zh) 2011-04-27
PL2265589T3 (pl) 2016-06-30
ES2577867T3 (es) 2016-07-19
WO2009115515A1 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
ECSP10010476A (es) Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6
MX2009003183A (es) Derivados de sulfonilpirazolincarboxamidina como antagonistas de 5-ht6.
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
CL2011000137A1 (es) Uso de compuestos derivados de 4,5-dihidro-oxazol-2-ilamina para tratar trastornos de ansiedad, trastornos bipolar, esquizofrenia, enfermedades neurológicas, epilepsias, migraña, trastornos metabólicos, trastornos cardiovasculares, entre otros; compuestos derivados de 4,5-dihidroxazol-2-ilamino; proceso de síntesis
UY32241A (es) Derivados de isoindol para el tratamiento de patologias relacionados con ab
NO20084375L (no) Imidazo[1,2-B]pyridaziner, deres fremstilling og deres anvendelse som GABA reseptorligander
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
DOP2011000130A (es) 1-(arilsulfonil)-4-(pepirazin-1-il)-1h-benzimidazol como ligando de 5-hidroxitriptamina-6
WO2007042544A3 (en) Imidazole derivatives and their use for modulating the gabaa receptor complex
DE602007013275D1 (de) Verbindungen mit kombinierten cannabinoid-cb1-antagonismus und acetylcholinesterasehemmung
MX363632B (es) Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos.
ATE552257T1 (de) Positive allosterische chinolizidinon-m1- rezeptormodulatoren
UY30529A1 (es) Compuestos de 1h-quinolin-4-ona, procedimientos, usos y composiciones
IL189974A0 (en) Benzimidazole derivatives and their use for modulating the gabaa receptor complex
MX2009005541A (es) Indoles que actuan como antagonistas del receptor v1a.
MX2009007405A (es) Compuestos con una combinacion de antagonismo de cb1 cannabinoide e inhibicion de recaptacion de serotonina.
MX2007012624A (es) Derivados de benzimidazol y su uso para la modulacion del complejo del receptor gaba-a.
NO20090972L (no) Pyrazolo[1,5-A]pyrimidiner, fremgangsmater, anvendelser og sammensetninger
MX2009005504A (es) Derivados de espiro piperidina como antagonistas del receptor via.
EA200970672A1 (ru) Соединения с комбинацией каннабиноид-свантагонизма и ингибирования обратного захвата серотонина
EA201071227A1 (ru) (5r)-1,5-диарил-4,5-дигидро-1h-пиразол-3-карбоксамидиновые производные, обладающие св1-антагонистической активностью
DE602007012683D1 (de) Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
CL2008003139A1 (es) Compuestos derivados de 6-(alcoxi o fenilalcoxi)-2,3-dihidro-indol-1-il-alquilaminas aciladas, con actividad en los receptores mt1 y mt2; composicion farmaceutica que los comprende; y uso en el tratamiento de alteraciones melatoninergicas tales como depresion, alteraciones del sueño y enfermedad de alzheimer.
UA98122C2 (ru) Производные сульфонилпиразол и сульфонилпиразолон карбоксамидина как антагонисты рецепторов 5-ht6
TW200730500A (en) 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators